Etorphine

Etorphine
Systematic (IUPAC) name
6,14-endoetheno – 7 a (1-(R)-hydroxy-1 methylbutyl)-tetrahydro-nororipavine
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
Legal status
Identifiers
CAS Number 14521-96-1 N
ATCvet code QN02AE90 (WHO)
PubChem CID 644209
DrugBank DB01497 YesY
ChemSpider 559231 YesY
UNII 42M2Y6NU9O YesY
KEGG D07937 YesY
ChEBI CHEBI:4912 N
ChEMBL CHEMBL287413 N
Chemical data
Formula C25H33NO4
Molar mass 411.53 g/mol
 NYesY (what is this?)  (verify)

Etorphine (M99) is a semi-synthetic opioid possessing an analgesic potency approximately 1,000–3,000 times that of morphine.[1] It was first prepared in 1960 from oripavine, which does not generally occur in opium poppy extract but rather in "poppy straw" and in the related plants Papaver orientale and Papaver bracteatum.[2] It was later reproduced in 1963 by a research group at MacFarlan Smith in Gorgie, Edinburgh, led by Professor Kenneth Bentley.[3] It can also be produced from thebaine.

Veterinary use

Etorphine is available legally only for veterinary use and is strictly governed by law. It is often used to immobilize elephants and other large mammals. Diprenorphine (M5050), also known as Revivon, is an opioid receptor antagonist that can be administered in proportion to the amount of etorphine used (1.3 times) to reverse its effects. Veterinary-strength etorphine is fatal to humans. For this reason the package as supplied to vets always includes the human antidote as well as Etorphine. The human antidote is generally naloxone, not diprenorphine, and is always prepared prior to the preparation of etorphine to be immediately administered following accidental human exposure to etorphine.

One of its main advantages is its speed of operation and, more importantly, the speed with which diprenorphine reverses the effects. The high incidence of side-effects, including severe cardiopulmonary depression, has caused etorphine to fall into disfavor in general veterinary practice. However, its high potency combined with the rapid action of both etorphine and its antagonist, diprenorphine, means that it has found a place for capture of large mammals such as rhinoceroses and elephants; under these circumstances both rapid onset and rapid recovery are very important characteristics. The high potency of etorphine means that sufficient etorphine can be administered to large wild mammals by projectile syringe (dart).

Large Animal Immobilon is a combination of etorphine plus acepromazine maleate. An etorphine antidote Large Animal Revivon contains mainly diprenorphine for animals and a human-specific naloxone-based antidote, which should be prepared prior to the etorphine. A 5–15 mg dose is enough to immobilize an African elephant and a 2–4 mg dose is enough to immobilize a Black Rhino.[4]

Pharmacology

Etorphine is an extremely potent, non-selective full agonist of the μ-, δ-, and κ-opioid receptors.[5][6] It also has relatively weak affinity for the nociceptin receptor.[7]

Legal status

In Hong Kong, Etorphine is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can be used legally only by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. Anyone who supplies the substance without prescription can be fined $10,000 (HKD). The penalty for trafficking or manufacturing the substance is a $5,000,000 (HKD) fine and life imprisonment. Possession of the substance for consumption without license from the Department of Health is illegal with a $1,000,000 (HKD) fine and/or 7 years of jail time.

In the Netherlands, Etorphine is a list I drug of the Opium Law. It is used only for veterinary purposes in zoos to immobilize large animals.

In the US, Etorphine is listed as a Schedule I drug with an ACSCN of 9056, although its hydrochloride salt is classified as Schedule II with an ACSCN of 9059. For both, the 2013 annual aggregate manufacturing quota for both was zero so presumably veterinary supplies of the hydrochloride are imported from Germany and/or the UK.

In the UK, under the Misuse of Drugs Act 1971, Etorphine is controlled as a Class A substance.

Synthesis

Etorphine synthesis:[8]

See also

References

  1. ↑ Bentley KW, Hardy DG (June 1967). "Novel analgesics and molecular rearrangements in the morphine-thebaine group. 3. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine". J. Am. Chem. Soc. 89 (13): 3281–92. doi:10.1021/ja00989a032. PMID 6042764.
  2. ↑ Aggrawal A (1995). "Chapter 3 Opium: the king of narcotics". Narcotic Drugs. New Delhi: National Book Trust. pp. xvi+161. ISBN 81-237-1383-5.
  3. ↑ Bentley KW, Hardy DG (1963). "New potent analgesics in the morphine series". Proceedings of the Chemical Society 220: 189–228. doi:10.1039/PS9630000189.
  4. ↑ "Etorphine HCl". Veterinary medicine for wildlife: immobilisation medicine for animals zoo animals. Zoo Pharm.
  5. ↑ Gavril Pasternak (17 April 2013). The Opiate Receptors. Springer Science & Business Media. pp. 444–. ISBN 978-1-60761-990-1.
  6. ↑ Gharagozlou, Parham; Hashemi, Ezzat; DeLorey, TimothyM; Clark, J David; Lameh, Jelveh (2006). BMC Pharmacology 6 (1): 3. doi:10.1186/1471-2210-6-3. ISSN 1471-2210. Missing or empty |title= (help)
  7. ↑ Hawkinson JE, Acosta-Burruel M, Espitia SA (February 2000). "Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors". Eur. J. Pharmacol. 389 (2-3): 107–14. doi:10.1016/S0014-2999(99)00904-8. PMID 10688973.
  8. ↑ Lewis, J. W.; Readhead, M. J. (1970). "Novel analgetics and molecular rearrangements in the morphine-thebaine group. XVIII. 3-Deoxy-6,14-endo-etheno-6,7,8,14-tetrahydrooripavines". Journal of Medicinal Chemistry 13 (3): 525–527. doi:10.1021/jm00297a041. PMID 5441135.

External links

This article is issued from Wikipedia - version of the Friday, April 15, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.